prostate cancer
Conditions
Interventions
HSPC Experimental group:ADT + Shenqi pill
HSPC control group:ADT + Shenqi pill
HSPC Blank group :ADT
CRPC Experimental group:ADT + Abiraterone + Shenqi pill + Xihuang pill
CRPC control group:ADT + Abiraterone + Shenqi pill + Xihuang pill
CRPC Blank group:ADT + Abiraterone
Sponsors
The First Affiliated Hospital of Hu'nan University of Chinese Medicine
Eligibility
Sex/Gender
Male
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: According to the "Chinese Society of Clinical Oncology (CSCO) Prostate Cancer Diagnosis and Treatment Guidelines 2020", Fizazi K and other research protocols were formulated. (Organized by the Guidelines Working Committee of the Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Prostate Cancer 2020. Beijing: People's Health Publishing House 2020, Fizazi K,et al. N Engl J Med, 2019:3 80(13): 1235-1246. 1. Inclusion criteria for patients in the HSPC experimental group:Metastatic prostate cancer (N1 and M1 stages): differentiate between low tumor burden metastases and high tumor burden metastases; locally advanced prostate cancer cannot be treated with radical prostatectomy or radiotherapy; after radical prostatectomy local recurrence but no further local therapy; distant metastasis after radical prostatectomy; 2. Inclusion criteria for patients in the CRPC experimental group: diagnosed as PCa,who have been treated with ADT for >= 3 months; serum testosterone reached the castration level (= 60 points, and are expected to survive for more than half a year; 4. Those who meet the syndrome of kidney-yang deficiency. The patients have good compliance and can conduct follow-up studies,understand and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Allergic to ADT drugs or abiraterone; 2. Severe heart, brain, liver, and kidney diseases at the same time; 3. Patients with primary malignant tumors combined with organs other than PCa; 4. End-stage tumor with multiple organ failures, the expected survival time < 6 months; 5. CRPC patients with liver metastases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival;progression-free survival;mismatch repair gene; | — |
Secondary
| Measure | Time frame |
|---|---|
| Physical condition assessment;appraisal of life quality; Evaluation of TCM symptoms; | — |
Countries
China
Contacts
Public ContactZhou Qing
The First Affiliated Hospital of Hu'nan University of Chinese Medicine
Outcome results
None listed